{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-003169","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.667314+00:00","generated_at":"2026-06-18T08:16:44.806595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProMIS Neurosciences reports 2022 net loss $18.1M, cash $5.9M, IND for PMN310 expected in 60 days","bullets":["Net loss $18.1M in 2022 vs $9.8M in 2021; cash $5.9M vs $16.9M.","R&D expenses rose to $16.1M from $4.6M, driven by PMN310 IND preparation.","IND for Alzheimer's candidate PMN310 expected within 60 days; Phase 1a planned.","Completed GLP toxicology for PMN310; no adverse effects at 5x planned highest dose.","Discovery programs: PMN267 (ALS) and PMN442 (MSA) selected and humanized."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-003169","json":"https://secwatch.observer/filing/0001558370-23-003169.json","markdown":"https://secwatch.observer/filing/0001558370-23-003169.md","text":"https://secwatch.observer/filing/0001558370-23-003169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023003169/0001558370-23-003169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023003169/pmn-20230308x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:16:44.806595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c32d60c1b7d4ca903a3a91e15a2750a382b0223d","claim":"ProMIS Neurosciences Inc. reported the year ended December 31, 2022 results: net income Net loss was $18.1 million for the year ended December 31, 2022, compared to $9.8 million for the same period in 2021..","evidence_excerpt":"reporting its financial condition and financial results as of and for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023003169/0001558370-23-003169-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $18.1 million for the year ended December 31, 2022, compared to $9.8 million for the same period in 2021."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}